TCGA-BA-6872-01A-11R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.087671233
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ANGIOGENESIS+0.390
- NOTCH_SIGNALING+0.330
- UV_RESPONSE_UP+0.330
- COAGULATION+0.320
- GLYCOLYSIS+0.320
- HYPOXIA+0.320
- PANCREAS_BETA_CELLS+0.320
- TNFA_SIGNALING_VIA_NFKB+0.310
Top 10 suppressed
- PROTEIN_SECRETION-0.310
- MITOTIC_SPINDLE-0.240
- ANDROGEN_RESPONSE-0.140
- ALLOGRAFT_REJECTION-0.130
- UV_RESPONSE_DN-0.120
- PEROXISOME-0.070
- BILE_ACID_METABOLISM-0.060
- FATTY_ACID_METABOLISM-0.050
- HEME_METABOLISM-0.040
- MYOGENESIS-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R111 | — | — | 0.857 |
| 2 | BS_X23724NJ | high-grade glioma | — | 0.855 |
| 3 | BS_QWTE1CWR | high-grade glioma | — | 0.828 |
| 4 | MDT-AP-2589 | Med | Medulloblastoma | 0.812 |
| 5 | X3a5c813b.6c47.49aa.916c.bcddbafdd54b | — | cohortA1 | 0.798 |
| 6 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.795 |
| 7 | ERR2208938 | — | — | 0.788 |
| 8 | MDT-AP-2001 | Med | Medulloblastoma | 0.787 |
| 9 | MDT-AP-0532 | Med | Medulloblastoma | 0.784 |
| 10 | BS_8RHPJ740 | Ependymoma NOS | — | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.330 | Idelalisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |